Literature DB >> 18956886

Human plasma contains cross-reactive Abeta conformer-specific IgG antibodies.

Brian O'Nuallain1, Luis Acero, Angela D Williams, Helen P McWilliams Koeppen, Alfred Weber, Hans P Schwarz, Jonathan S Wall, Deborah T Weiss, Alan Solomon.   

Abstract

Two conformers of aggregated Abeta, i.e., fibrils and oligomers, have been deemed important in the pathogenesis of Alzheimer's disease. We now report that intravenous immune globulin (IVIG) derived from pools of human plasma contains IgGs that recognize conformational epitopes present on fibrils and oligomers, but not their soluble monomeric precursor. We have used affinity chromatography to isolate these antibodies and have shown that they cross-reacted with comparable nanomolar avidity with both types of Abeta aggregates; notably, binding was not inhibited by soluble Abeta monomers. Our studies provide further support for investigating the therapeutic use of IVIG in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18956886     DOI: 10.1021/bi801767k

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  21 in total

Review 1.  Immunological origin and functional properties of catalytic autoantibodies to amyloid beta peptide.

Authors:  Sudhir Paul; Stephanie Planque; Yasuhiro Nishiyama
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

Review 2.  [Administration of intravenous immunoglobulins in neurology. An evidence-based consensus: update 2010].

Authors:  M Stangel; R Gold
Journal:  Nervenarzt       Date:  2011-04       Impact factor: 1.214

Review 3.  Amyloid beta: structure, biology and structure-based therapeutic development.

Authors:  Guo-Fang Chen; Ting-Hai Xu; Yan Yan; Yu-Ren Zhou; Yi Jiang; Karsten Melcher; H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2017-07-17       Impact factor: 6.150

4.  A human monoclonal IgG that binds aβ assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo.

Authors:  Yona Levites; Brian O'Nuallain; Rama Devudu Puligedda; Tomas Ondrejcak; Sharad P Adekar; Cindy Chen; Pedro E Cruz; Awilda M Rosario; Sallie Macy; Alexandra J Mably; Dominic M Walsh; Ruben Vidal; Alan Solomon; Daniel Brown; Michael J Rowan; Todd E Golde; Scott K Dessain
Journal:  J Neurosci       Date:  2015-04-22       Impact factor: 6.167

5.  Inherent anti-amyloidogenic activity of human immunoglobulin gamma heavy chains.

Authors:  Sharad P Adekar; Igor Klyubin; Sally Macy; Michael J Rowan; Alan Solomon; Scott K Dessain; Brian O'Nuallain
Journal:  J Biol Chem       Date:  2009-11-04       Impact factor: 5.157

6.  A monoclonal antibody against synthetic Aβ dimer assemblies neutralizes brain-derived synaptic plasticity-disrupting Aβ.

Authors:  Brian O'Nuallain; Igor Klyubin; Jessica M Mc Donald; James S Foster; Alfred Welzel; Andrew Barry; Richard K Dykoski; James P Cleary; Martijn F B G Gebbink; Michael J Rowan; Dominic M Walsh
Journal:  J Neurochem       Date:  2011-08-22       Impact factor: 5.372

Review 7.  Invasive and non-invasive therapies for Alzheimer's disease and other amyloidosis.

Authors:  Gaurav Pandey; Vibin Ramakrishnan
Journal:  Biophys Rev       Date:  2020-09-15

8.  Anti-amyloidogenic activity of IgGs contained in normal plasma.

Authors:  Brian O'Nuallain; Angela D Williams; Helen P McWilliams-Koeppen; Luis Acero; Alfred Weber; Hartmut Ehrlich; Hans P Schwarz; Alan Solomon
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

9.  Amyloid-β oligomer specificity mediated by the IgM isotype--implications for a specific protective mechanism exerted by endogenous auto-antibodies.

Authors:  Malin Lindhagen-Persson; Kristoffer Brännström; Monika Vestling; Michael Steinitz; Anders Olofsson
Journal:  PLoS One       Date:  2010-11-10       Impact factor: 3.240

Review 10.  Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence.

Authors:  Richard Dodel; Frauke Neff; Carmen Noelker; Refik Pul; Yansheng Du; Michael Bacher; Wolfgang Oertel
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.